Interações de Venlafaxina

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (bula de Amiodarona, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Anfetamina, Advertências e precauções)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (bula de Anfetamina + dextroanfetamina, Advertências e precauções)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (bula de Azitromicina, Advertências e precauções)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (bula de Venlafaxina, Contraindicações)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Beladona + ópio, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Buprenorfina, Interações medicamentosas)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Buprenorfina + naloxona, Interações medicamentosas)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Butalbital + paracetamol + cafeína + codeína, Interações medicamentosas)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Butorfanol, Precauções)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (bula de Carbamazepina, Contraindicações)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Ciprofloxacino, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Codeína, Interações medicamentosas)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (bula de Dextroanfetamina, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (bula de Dofetilida, Advertências)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (bula de Dronedarona, Contraindicações)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (bula de Edoxabana, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (bula de Entricitabina + rilpivirina + tenofovir, Advertências e precauções)

Combinar a erva-de-são-joão (hipérico) com antidepressivos e outros medicamentos serotoninérgicos aumenta o risco de síndrome serotoninérgica. (NCCIH, St. John's Wort)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Drugs that Prolong the QT Interval : Avoid concomitant use. (bula de Fenobarbital, Interações medicamentosas)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Fentanila, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (bula de Fluconazol, Contraindicações)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (bula de Flumazenil, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (bula de Foscarnete, Interações medicamentosas)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (bula de Fosfomicina, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona, Interações medicamentosas)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + clorfeniramina, Interações medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + homatropina, Interações medicamentosas)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + ibuprofeno, Precauções)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + paracetamol, Precauções)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidromorfona, Interações medicamentosas)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (bula de Hidroxicloroquina, Advertências e precauções)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (bula de Iloperidona, Interações medicamentosas)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (bula de Venlafaxina, Contraindicações)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (bula de Ivabradina, Advertências e precauções)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (bula de Levofloxacino, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Levorfanol, Precauções)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (bula de Venlafaxina, Contraindicações)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Lisdexanfetamina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Lopinavir + ritonavir, Advertências e precauções)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (bula de Lorazepam, Advertências e precauções)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Metadona, Advertências e precauções)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Metanfetamina, Advertências e precauções)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (bula de Metaxalona, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Morfina, Interações medicamentosas)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oliceridina, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (bula de Oxaliplatina, Interações medicamentosas)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (bula de Oxicodona, Interações medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oximorfona, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Paracetamol + codeína, Precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (bula de Pazopanibe, Interações medicamentosas)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Pentazocina + naloxona, Precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (bula de Pimozida, Contraindicações)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (bula de Prometazina, Interações medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Prometazina + codeína, Interações medicamentosas)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (bula de Propafenona, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (bula de Venlafaxina, Contraindicações)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Remifentanila, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (bula de Venlafaxina, Contraindicações)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (bula de Tetrabenazina, Interações medicamentosas)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (bula de Tioridazina, Contraindicações)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (bula de Vepdegestranto, Advertências e precauções)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (bula de Venlafaxina, Advertência em caixa preta)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (bula de Ziprasidona, Contraindicações)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (bula de Venlafaxina, Advertências e precauções)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (bula de Arformoterol, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (bula de Articaína + epinefrina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (bula de Brimonidina, Interações medicamentosas)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (bula de Brimonidina + timolol, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (bula de Bupivacaína, Advertências e precauções)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (bula de Bupivacaína + epinefrina, Advertências e precauções)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (bula de Carisoprodol, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (bula de Clonazepam, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (bula de Clorazepato, Interações medicamentosas)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (bula de Cloroprocaína, Precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (bula de Cocaína, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (bula de Daridorexanto, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Desflurano, Advertências e precauções)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (bula de Desmopressina, Interações medicamentosas)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (bula de Venlafaxina, Interações medicamentosas)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (bula de Dicicloverina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (bula de Dronabinol, Advertências e precauções)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (bula de Droperidol, Advertências)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (bula de Epinefrina (adrenalina), Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (bula de Eribulina, Advertências e precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (bula de Escopolamina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (bula de Eszopiclona, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (bula de Fenilefrina, Interações medicamentosas)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (bula de Fenitoína, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (bula de Fisostigmina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Fluticasona + salmeterol, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (bula de Formoterol, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (bula de Fosfenitoína, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (bula de Gefitinibe, Interações medicamentosas)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (bula de Glicopirrônio, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Gosserrelina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Haloperidol: Increase in Haloperidol AUC and C max . (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (bula de Ipratrópio + salbutamol, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Isoflurano, Advertências e precauções)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (bula de Isoprenalina (isoproterenol), Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

TYKERB may prolong the QT interval in some patients. (bula de Lapatinibe, Advertências e precauções)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (bula de Lemborexanto, Advertências e precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Leuprorrelina, Advertências e precauções)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (bula de Levossalbutamol, Interações medicamentosas)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (bula de Levotiroxina, Interações medicamentosas)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (bula de Lidocaína, Interações medicamentosas)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (bula de Lidocaína + epinefrina, Advertências e precauções)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (bula de Liotironina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (bula de Lumateperona, Advertências e precauções)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (bula de Lurasidona, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (bula de Mefloquina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (bula de Mepivacaína, Advertências)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (bula de Metilescopolamina, Interações medicamentosas)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (bula de Venlafaxina, Interações medicamentosas)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (bula de Venlafaxina, Interações medicamentosas)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (bula de Metronidazol, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (bula de Moxifloxacino, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (bula de Venlafaxina, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (bula de Oxibato de sódio, Advertências e precauções)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (bula de Paliperidona, Advertências e precauções)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (bula de Ponesimode, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (bula de Prilocaína + epinefrina, Interações medicamentosas)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (bula de Primaquina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (bula de Quetiapina, Advertências e precauções)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (bula de Rifampicina, Interações medicamentosas)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (bula de Rifapentina, Interações medicamentosas)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (bula de Rilpivirina, Advertências e precauções)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (bula de Rocurônio, Advertências e precauções)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Salbutamol, Interações medicamentosas)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Salmeterol, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (bula de Sevoflurano, Advertências)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (bula de Sotalol, Interações medicamentosas)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (bula de Subcitrato de bismuto + metronidazol + tetraciclina, Advertências e precauções)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (bula de Sulfametoxazol + trimetoprima, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (bula de Temazepam, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (bula de Venlafaxina, Interações medicamentosas)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (bula de Terbutalina, Precauções)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (bula de Toremifeno, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Triptorrelina, Advertências e precauções)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (bula de Umeclidínio + vilanterol, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (bula de Venlafaxina, Interações medicamentosas)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (bula de Vasopressina, Interações medicamentosas)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (bula de Venlafaxina, Interações medicamentosas)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (bula de Venlafaxina, Interações medicamentosas)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (bula de Zaleplona, Interações medicamentosas)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (bula de Zolpidem, Advertências e precauções)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Ácido valproico, Interações medicamentosas)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (bula de Venlafaxina, Interações medicamentosas)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (bula de Venlafaxina, Interações medicamentosas)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (bula de Venlafaxina, Advertências e precauções)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (bula de Benzatropina, Advertências)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (bula de Brexpiprazol, Advertências e precauções)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (bula de Venlafaxina, Interações medicamentosas)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (bula de Carbidopa, Interações medicamentosas)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (bula de Cariprazina, Advertências e precauções)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (bula de Venlafaxina, Interações medicamentosas)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (bula de Hidroxizina, Precauções)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (bula de Lovastatina, Advertências)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (bula de Perfenazina, Interações medicamentosas)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (bula de Tiagabina, Advertências)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (bula de Triexifenidil, Interações medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (bula de Venlafaxina, Advertências e precauções)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (bula de Venlafaxina, Interações medicamentosas)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (bula de Venlafaxina, Interações medicamentosas)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (bula de Aripiprazol, Interações medicamentosas)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (bula de Entacapona, Precauções)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (bula de Ropinirol, Interações medicamentosas)